Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Antimicrobial Agents and Chemotherapy|July 11, 2018
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosisClara Aguilar-Pérez, Begoña Gracia, Liliana Rodrigues, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2014
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosisMayra Silva-Miranda, Euloge Ekaza, Adrien Breiman, et al.
Cell Host & Microbe|September 5, 2017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected MacrophagesPedro Escoll, Ok-Ryul Song, Flávia Viana, et al.
Frontiers in Pharmacology|April 30, 2019
Mycolactone as Analgesic: Subcutaneous Bioavailability ParametersJérémie Babonneau, Dimitri Bréard, Marie-Line Reynaert, et al.
Infection and Immunity|March 23, 2006
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosisLaleh Majlessi, Marcela Simsova, Zdenka Jarvis, et al.
Frontiers in Cellular and Infection Microbiology|March 20, 2023
An image-based high-content screening for compounds targeting <i>Toxoplasma gondii</i> repurposed inhibitors effective against the malaria parasite <i>Plasmodium falciparum</i>Ariane Honfozo, Rodrigue Houngue, Alexandre Vandeputte, et al.
Vaccine|April 15, 2015
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion systemDaria Bottai, Wafa Frigui, Simon Clark, et al.
Plos One|January 7, 2020
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compoundsGarrett C Moraski, Nathalie Deboosère, Kate L Marshall, et al.
Plos Pathogens|February 20, 2008
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoPWafa Frigui, Daria Bottai, Laleh Majlessi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2017
<i>Mycobacterium tuberculosis</i> inhibits human innate immune responses via the production of TLR2 antagonist glycolipidsLandry Blanc, Martine Gilleron, Jacques Prandi, et al.
Pageof 12